AOD-9604

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminal fragment (amino acids 176-191) of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus. It was developed by Metabolic Pharmaceuticals Limited in Australia in the late 1990s as a potential anti-obesity therapeutic that could replicate the fat-burning effects of growth hormone without its unwanted side effects.

The fundamental insight behind AOD-9604 is that the fat-metabolizing activity of hGH is concentrated in a specific region of the molecule, separate from its growth-promoting and diabetogenic effects. By isolating and modifying this fragment, researchers created a peptide that stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without increasing IGF-1 levels, causing insulin resistance, or promoting cellular proliferation.

Key facts about AOD-9604:

• Origin: Modified fragment of human growth hormone (amino acids 176-191 + tyrosine)
• Developer: Metabolic Pharmaceuticals, Melbourne, Australia
• Molecular weight: Approximately 1,817 Da
• Mechanism: Stimulates lipolysis via beta-3 adrenergic receptor pathway
• Key advantage: Fat loss activity without hGH side effects (no IGF-1 increase, no hyperglycemia)
• TGA status: Received GRAS (Generally Recognized as Safe) status from the Australian TGA for use in food products

Mechanism of Action

AOD-9604 promotes fat loss through several well-characterized and distinct biochemical pathways, differentiating it from full-length growth hormone and other fat loss agents.

1. Beta-3 Adrenergic Receptor Stimulation

AOD-9604’s primary fat-burning mechanism involves the beta-3 adrenergic receptor pathway:

• Activates beta-3 adrenergic receptors on adipocytes (fat cells), particularly in visceral and abdominal fat depots
• Triggers the cAMP cascade within fat cells, activating protein kinase A
• Upregulates hormone-sensitive lipase (HSL), the enzyme that breaks triglycerides into free fatty acids and glycerol
• Enhances lipolysis (the release of stored fat) for use as energy

This pathway mirrors one of the key mechanisms by which full-length hGH promotes fat loss, but AOD-9604 achieves it without activating the growth-promoting portions of the GH receptor.

2. Lipogenesis Inhibition

Beyond breaking down existing fat, AOD-9604 also prevents new fat accumulation:

• Inhibits lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase
• Reduces the conversion of carbohydrates to stored fat
• Decreases triglyceride uptake by adipocytes
• May reduce differentiation of pre-adipocytes into mature fat cells

This dual action (increasing fat breakdown while decreasing fat storage) explains why AOD-9604 can produce meaningful body composition changes over time.

3. No Effect on IGF-1 or Blood Glucose

What makes AOD-9604 particularly notable among GH-related peptides is what it does NOT do:

• Does not increase IGF-1 (insulin-like growth factor 1) levels, avoiding the growth-promoting and potentially pro-cancer effects of full GH
• Does not cause hyperglycemia or insulin resistance, unlike full-length hGH
• Does not promote cellular proliferation (growth of tissues, organs, or tumors)
• Does not affect bone growth or collagen synthesis
• Does not alter thyroid function markers in clinical studies

This clean side effect profile was confirmed in multiple clinical trials and is the primary rationale for AOD-9604’s development over full-length GH for obesity treatment.

4. Mitochondrial Fat Oxidation Enhancement

Emerging research suggests AOD-9604 may also enhance fat utilization at the mitochondrial level:

• Increases fatty acid transport into mitochondria for beta-oxidation
• Upregulates carnitine palmitoyltransferase (CPT-1), the rate-limiting enzyme for mitochondrial fat burning
• May enhance uncoupling protein activity, increasing metabolic rate
• Supports the mobilization of fatty acids released by lipolysis for actual energy production rather than re-esterification

Research Evidence

Clinical Trials

AOD-9604 has undergone more formal clinical testing than many other research peptides, progressing through Phase I, II, and III human trials.

Phase IIb Clinical Trial (Metabolic Pharmaceuticals, 2004):

• 300 obese individuals randomized to AOD-9604 or placebo
• 12-week treatment period
• The 1mg/day oral dose group showed statistically significant fat loss compared to placebo
• No significant adverse events; no changes in IGF-1, glucose, or insulin levels
• Results were described as modest, which contributed to challenges in the drug’s commercial development

Phase I Safety Studies:

• AOD-9604 demonstrated a favorable safety profile across multiple dose ranges
• No clinically significant changes in blood glucose, insulin, or IGF-1
• No serious adverse events attributed to the peptide
• Pharmacokinetic profile confirmed absorption and activity

Phase III Trial (2007):

• Larger-scale trial with oral AOD-9604
• Results were described as not meeting the primary efficacy endpoint for obesity drug approval standards
• However, body composition improvements were observed
• The trial used oral administration, which has significantly lower bioavailability than subcutaneous injection

Australian TGA Status

In a notable regulatory development:

• AOD-9604 received GRAS (Generally Recognized as Safe) status from the Australian Therapeutic Goods Administration (TGA)
• This designation was specifically for inclusion in food products, not as a standalone therapeutic
• The safety designation reflects the extensive safety data collected during clinical trials
• Australia has taken a more progressive regulatory approach to AOD-9604 than the United States

Animal Research

Extensive preclinical research supports AOD-9604’s fat loss mechanisms:

Obese mouse models (Heffernan et al., 2001):

• AOD-9604 reduced body weight and body fat in obese mice
• Did not affect IGF-1 levels or blood glucose (unlike full-length GH)
• Fat loss was comparable to that produced by full-length hGH
• No antibodies to hGH developed (important safety finding)

Zucker rats (genetically obese):

• Chronic AOD-9604 administration reduced fat mass
• Improved metabolic parameters without affecting lean mass
• Confirmed the selective lipolytic activity

Cartilage and Joint Research:

• Interestingly, AOD-9604 has also been studied for cartilage repair
• Showed chondroprotective properties in animal models
• Some Australian clinics have explored its use for osteoarthritis
• This application is separate from its fat loss properties

AOD-9604 vs. Other Fat Loss Compounds

AOD-9604 vs. Full-Length hGH

AOD-9604 vs. GH-Releasing Peptides (CJC-1295/Ipamorelin)

• GH-releasing peptides stimulate your body’s own GH production, providing both fat loss and anabolic benefits but also increasing IGF-1
• AOD-9604 provides isolated fat loss without any GH-related side effects
• Combination approach: Many protocols stack AOD-9604 with CJC-1295/Ipamorelin for comprehensive body recomposition

AOD-9604 vs. Pharmaceutical Weight Loss Drugs

• Semaglutide/Tirzepatide (GLP-1 agonists): More potent appetite suppression and weight loss, but cause significant muscle loss and GI side effects; FDA-approved
• AOD-9604: More targeted fat loss without appetite suppression; preserves lean mass; not FDA-approved
• Different mechanisms: GLP-1 agonists primarily reduce appetite; AOD-9604 directly stimulates fat metabolism

Dosing Protocols

Standard Fat Loss Protocol

Aggressive Fat Loss Protocol (with GH peptides)

This combination provides both direct lipolysis (AOD-9604) and enhanced natural GH release (CJC/Ipa), optimizing fat loss while also supporting lean tissue maintenance.

Body Recomposition Protocol

The combination of AOD-9604 with L-Carnitine and fasted cardio maximizes fatty acid mobilization and oxidation. AOD-9604 liberates fatty acids from adipocytes, L-Carnitine shuttles them into mitochondria, and exercise burns them for fuel.

Diet and Exercise Requirements

AOD-9604 is not a magic bullet and produces best results when combined with proper nutrition and exercise:

Nutrition Guidelines

• Caloric deficit: AOD-9604 enhances fat loss but works best with a moderate caloric deficit (300-500 calories below maintenance)
• Protein intake: Maintain 0.8-1g per pound of body weight to preserve lean mass
• Carbohydrate timing: Focus carbohydrates around training; keep them moderate at other meals
• Fat intake: Moderate healthy fats (0.3-0.4g per pound); do not go extremely low-fat as this can impair hormonal function
• Fasting window: Many users take AOD-9604 during a morning fasting window and delay their first meal by 1-2 hours

Exercise Recommendations

• Fasted cardio: 30-45 minutes of moderate-intensity cardio after morning AOD-9604 injection maximizes fat oxidation
• Resistance training: Maintain a consistent strength program to preserve and build lean mass during fat loss
• HIIT: 2-3 sessions per week can enhance metabolic rate and fat oxidation
• NEAT (Non-Exercise Activity Thermogenesis): Increase daily movement (walking, standing) to support overall energy expenditure

Reconstitution and Storage

Preparation

1. Starting material: Lyophilized AOD-9604 powder (typically 2mg or 5mg per vial)
2. Reconstitution: Add bacteriostatic water (for a 5mg vial, add 2.5mL for 200mcg per 0.1mL; or 5mL for 100mcg per 0.1mL)
3. Technique: Direct water stream along vial wall; swirl gently, never shake
4. Solution: Should be clear and colorless

Storage

• Unreconstituted: Refrigerated (2-8°C) for up to 12 months; frozen for longer storage
• Reconstituted: Refrigerate immediately; use within 3-4 weeks
• Protect from light and heat: Store in original box or wrapped in foil
• Travel: Keep cold during transport; peptide stability degrades rapidly at room temperature

Side Effects

Common (generally mild)

• Injection site reactions: Redness, mild swelling, or itching at injection site; typically resolves within 30-60 minutes
• Mild headache: Occasionally reported in the first week of use
• Slight nausea: Usually transient, more common when taken without adequate hydration
• Flushing: Brief warmth or flushing after injection

Uncommon

• Mild hypoglycemia symptoms: Rare, but possible in individuals on caloric restriction; ensure adequate nutrition
• Water retention fluctuations: Some users report temporary shifts in water weight
• Fatigue: Occasionally reported during the first few days; usually resolves
• Mild GI discomfort: Rare; more associated with oral formulations

What AOD-9604 Does NOT Typically Cause

• No insulin resistance or blood sugar elevation
• No IGF-1 increase
• No water retention (unlike full GH)
• No carpal tunnel syndrome
• No joint pain or swelling
• No organ growth (acromegaly risk)
• No significant hormonal disruption

Contraindications

• Active cancer or history of malignancy (though AOD-9604 does not increase IGF-1, caution is warranted with any growth-factor-related peptide)
• Pregnancy and breastfeeding (insufficient safety data)
• Type 1 diabetes (consult physician; potential interactions with insulin dosing)
• Active eating disorders (any fat loss compound may exacerbate disordered eating behaviors)
• Known hypersensitivity to AOD-9604 or its components
• Children and adolescents (not studied in pediatric populations)

WADA and Athletic Competition

AOD-9604 is prohibited by WADA (World Anti-Doping Agency):

• Classified under S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics
• Banned both in-competition and out-of-competition
• Detectable via anti-doping testing methods
• Notable case: Several Australian Football League (AFL) players were investigated in 2013 for AOD-9604 use (the “Essendon supplements saga”)
• Athletes subject to anti-doping testing must not use AOD-9604

Frequently Asked Questions

Does AOD-9604 build muscle?

No. Unlike full-length growth hormone, AOD-9604 does not stimulate IGF-1 production or promote muscle protein synthesis. Its effects are limited to fat metabolism. For muscle-building effects, consider combining AOD-9604 with GH-releasing peptides (CJC-1295/Ipamorelin) or other anabolic agents.

How is AOD-9604 different from taking hGH for fat loss?

AOD-9604 provides the fat-burning fragment of hGH without the full molecule’s side effects. You get targeted lipolysis without insulin resistance, IGF-1 elevation, water retention, carpal tunnel, or organ growth. The tradeoff is that you also do not get hGH’s muscle-building, skin-improving, or recovery-enhancing effects.

Can I take AOD-9604 with other peptides?

Yes. AOD-9604 is commonly stacked with CJC-1295 and Ipamorelin for comprehensive body recomposition. It can also be used alongside BPC-157 or TB-500 if you are addressing injuries concurrently. Avoid combining with other fat-loss drugs (clenbuterol, T3, DNP) without medical supervision.

Why did AOD-9604 fail in clinical trials?

The Phase III trial used oral administration, which has substantially lower bioavailability than subcutaneous injection. The oral dosing may not have provided sufficient blood levels for robust efficacy. Additionally, regulatory standards for obesity drugs require substantial weight loss (typically 5-10% above placebo), and AOD-9604’s effects, while real, were modest by pharmaceutical standards. Many practitioners believe subcutaneous AOD-9604 at appropriate doses is more effective than the oral formulations tested in trials.

How long until I see results?

Most users report noticing subtle changes by weeks 2-3, with meaningful body composition improvements by weeks 6-8. Optimal results typically require a full 12-week cycle combined with proper diet and exercise. Users who are closer to their goal weight may notice changes sooner; those with more fat to lose may need longer protocols.

Do I need to diet while using AOD-9604?

While AOD-9604 can promote fat loss even at maintenance calories, results are significantly better with a moderate caloric deficit. Think of AOD-9604 as an enhancer of your fat loss efforts, not a replacement for them. A well-structured diet and exercise program will multiply the peptide’s effects.

Legal Status

AOD-9604 is:

• Not FDA-approved for any human use in the United States
• Available as a research chemical from peptide suppliers
• GRAS status in Australia via the TGA for food product inclusion
• Banned by WADA for competitive athletes
• Legal to possess in most jurisdictions for research purposes
• Prescribed off-label by some physicians through compounding pharmacies

Medical Disclaimer

This article is for educational and informational purposes only. AOD-9604 is a research peptide not approved by the FDA for human use. While it has undergone more clinical testing than many research peptides, it did not achieve regulatory approval as a weight loss medication. Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before using any peptide or research compound. Self-administration of injectable peptides carries inherent risks including infection, dosing errors, and unknown long-term effects. AOD-9604 is prohibited by WADA; athletes should verify compliance with their sport’s anti-doping regulations. The regulatory status of AOD-9604 varies by jurisdiction; verify current legality in your area.